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Abstract 
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the 
past decade. As the number of available agents, and related volume of research, has grown, 
it is increasingly complex to know how to optimally treat patients. The authors are 
practicing medical oncologists at the US Oncology Network, the largest community-based 
network of oncology providers in the country, and represent the leadership of the Network’s 
Genitourinary Research Committee. We outline our thought process in approaching 
sequential therapy of mRCC and the use of real-world data to inform our approach. We also 
highlight the evolving literature that will impact practicing oncologists in the near future. 
Keywords: kidney cancer; renal cell carcinoma; sequential therapy 
Received: 29 December 2015; Accepted after revision: 22 February 2016; Published: 05 April 2016. 
Author for correspondence: Bradford Hirsch, MD, 7777 Forest Lane, Suite D-400, Dallas, TX 75230. Email: 
Bradford.Hirsch@USOncology.com 
How to cite: Hirsch BR, Burke JM, Agrawal M, Hauke RJ, Hutson TE, Doshi G, et al. Sequential  
therapy in metastatic renal cell carcinoma. J Kidney Cancer VHL 2016;3(1):23–35. Doi: 
http://dx.doi.org/10.15586/jkcvhl.2016.46 
Copyright: The Authors. 
License: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). 
http://creativecommons.org/licenses/by/4.0 
Introduction
The treatment of metastatic renal cell 
carcinoma (mRCC) has changed 
dramatically in the past decade. Between 
2005 and 2012, six new therapies were 
approved for patients with metastatic 
disease, in addition to the older therapies 
of interferon and high-dose interleukin-2 
(IL-2) (1). Furthermore, the introduction of 
new agents is not slowing. In September 
2015, two landmark articles on nivolumab 
and cabozantanib in the New England 
Journal of Medicine advanced the field 
further (2, 3). Although the new therapies 
improve outcomes of patients with 
metastatic disease, there remain as many 
questions as answers about how best to 
incorporate the options into treatment 
algorithms for patients, creating a 
challenge for practicing oncologists. 
To keep up with all of the literature is a 
daunting task. Guidelines published by 
groups such as the National Comprehensive 
Cancer Network (NCCN) help to guide 
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treatment selection (4), yet often the 
multitude of choices can leave a 
practitioner uncertain as to which agent to 
select for a patient. There are also 
alternative guidelines such as those 
released by the European Association of 
Urology and the European Society for 
Medical Oncology (ESMO) (5, 6). As an 
example, the most recent NCCN guidelines 
list six therapeutic options for the first-line 
treatment of mRCC—sunitinib (Sutent, 
Pfizer), temsirolimus (Torisel, Pfizer), 
bevacizumab (Avastin, Roche/Genentech),  
interferon, pazopanib (Votrient, Novartis), 
high-dose IL-2, and sorafenib (Nexavar, 
Bayer)—as well as clinical trials and best 
supportive care. Other guidelines, such as 
those released in 2014 by ESMO, refer to 
stronger evidence for some, but are still 
quite inclusive. Despite the overlap in some 
of the classes of agents among these 
options, there is variability in their toxicity 
and efficacy profiles, so they are not readily 
interchangeable. Choice of second-line 
therapy and beyond becomes complex as 
many agents are available, including 
axitinib (Inlyta, Pfizer), everolimus (Afinitor, 
Novartis), sorafenib (Nexavar, Bayer), and 
nivolumab (Opdivo, Bristol-Meyers Squibb). 
To further complicate the picture, patients 
often become sicker as the disease 
progresses, forcing physicians to 
incorporate other considerations such as 
performance status, comorbidities, and 
preferences regarding end-of-life care into 
decisions about treatment options; in fact, 
evidence suggests that only about 50% of 
patients in the United States receive 
second-line therapy, as opposed to best 
supportive care (7). Italian analyses 
similarly showed that approximately 50% 
of patients received second-line therapy, 
and only 13% of patients received third-line 
therapy (8, 9). 
The authors are practicing medical 
oncologists at the US Oncology Network 
(USON), the largest community-based 
network of oncology providers in the 
country, who treat relatively high volumes 
of mRCC patients as members of the 
Genitourinary Research Committee. 
Herein, we outline our thought process in 
approaching sequential therapy of mRCC. 
The discussion represents our present 
approach and provides a framework upon 
which new agents and evidence need to be 
incorporated as they are introduced over 
the next months and years. Our experience 
is further advanced by the “real-world 
data” analyses that occur within the USON, 
leveraging the data generated by our 
treatments to provide new insights into 
how agents perform in routine clinical care. 
Such real-world data are critically 
important in order to demonstrate the 
external validity of the trial data upon 
which the guidelines are based. 
Standard of care in the first-line therapy 
Although there are six treatments listed as 
first-line options as per the NCCN 
guidelines, treatment selection becomes 
more manageable once patients are 
stratified according to risk category. We 
recommend risk stratification of patients 
according to the Memorial Sloan Kettering 
Cancer Center (MSKCC) criteria (10). As 
shown in Table 1, patients were 
categorized by five criteria into risk 
groups: good-risk (0 risk factors), 
intermediate-risk (1–2), or poor-risk (≥ 3). 
The Heng criteria were published following 
the introduction of subsequent agents and 
can alternatively be used for risk 
stratification (11). Both frameworks have 
significant prognostic implications with 
differences in the median overall survival 
(OS) in the original MSKCC trial of 19.9 
months in the good-risk group compared 
with 3.9 months in the poor-risk group. In 
the Heng analysis (post introduction of 
newer agents), median OS was not 
reached in the good-risk group, was 27 
months in the intermediate-risk group, 
and was 8.8 months in the poor-risk 
group. Neither is ideal because they do not 
fully account for the present era of 
targeted agents; however, they remain 
widely used due to their simplicity and the 
lack of alternative, validated tools. Based 
on this stratification, patients may be 
taken down different first- and second-line 
treatment pathways as shown in Figure 1. 
We outline the logic behind these 
treatment considerations subsequently. 
Good-risk patients: role of IL-2 
For patients who are young, otherwise 
healthy, and wish to be maximally 
aggressive, high-dose IL-2 can be 
considered. In one study, treatment with 
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Table 1. Memorial Sloan Kettering Cancer Center (MSKCC) (10) and Heng risk (11) stratification 
Variables Cutoff MSKCC Heng 
Karnofsky performance status <80% X X 
Hemoglobin <ULN X X 
Calcium >10 X X 
Time from diagnosis to treatment <1 year X X 
LDH >1.5× ULN X  
Platelet count >ULN  X 
Neutrophil count >ULN  X 
ULN: upper limit of normal. 
Risk groups are defined as 0 risk factors = favorable, 1–2 risk factors = intermediate, and >2 
risk factors = poor. 
high-dose IL-2 achieved objective responses 
in 20% of patients, with complete responses 
(CRs) in 9% (12). To date, no other agent 
approved in the treatment of mRCC has 
achieved similar CR results. The toxicity 
and intensity of treatment are quite high. 
Dave deBronkart (e-Patient Dave) gives talks 
about how his disease was cured by his 
search of the Internet, identification of IL-2 
as an option, and active pursuit of it after 
his physicians failed to inform him about its 
availability (13). Patients should be able to 
similarly weigh the pros and cons of the 
various treatment options. However, as 
discussed subsequently, few receive the 
agent in practice. 
Intermediate-risk patients: role of sunitinib 
vs pazopanib 
About half of patients with mRCC fall into 
the intermediate-risk category (10). Not 
taking into account clinical trials, the choice 
presently is largely between pazopanib and 
sunitinib for this cohort for the reasons 
outlined in the “other considerations” 
section. For these two agents, the landmark 
trials demonstrated an OS benefit for each 
agent, as shown in Table 2; however, the 
results cannot be clearly extrapolated to 
demonstrate a “preferred” agent. Two 
subsequent studies have informed care. The 
first is the COMPARZ (Pazopanib vs sunitinib 
in the treatment of locally advanced and/or 
metastatic renal cell carcinoma) trial (14). In 
this trial, 1,110 patients with clear cell 
mRCC were randomized to pazopanib at 800 
mg daily or sunitinib at 50 mg on a 4-week 
on and a 2-week off schedule. The primary 
endpoint was progression-free survival (PFS), 
and the trial was powered for non-inferiority, 
and not for superiority. The hazard ratio (HR) 
was 1.05 with a 95% confidence interval (CI) 
of 0.90 to 1.22. The upper bound of the CI 
for non-inferiority was predetermined at 
1.25, so the trial just met the goal of non-
inferiority. There continues to be controversy 
related to the study design. For instance, 
true non-inferiority would require both the 
intention-to-treat and per-protocol 
approaches to meet the predetermined cut 
off; however, the CI for the per-protocol had 
an upper bound of 1.25, equaling the pre-
specified cutoff. Despite these limitations, the 
patient experiences favored pazopanib in 
terms of fatigue (63% with sunitinib vs 55% 
with pazopanib), hand-foot syndrome (50% 
vs 29%), and thrombocytopenia (78% vs 
41%). Eleven of 14 Health Related Quality of 
Life (HRQoL) domains also favored 
pazopanib. Of note, liver function 
abnormalities were higher with pazopanib 
(60% vs 43%). The conclusion of the authors 
was that pazopanib and sunitinib have 
similar efficacy as first-line therapy, but the 
best available toxicity information favors 
pazopanib. 
The second trial of relevance is PISCES 
(Patient preference study of pazopanib vs 
sunitinib in advanced or metastatic kidney 
cancer) (15). A total of 169 patients were 
randomized to either pazopanib or sunitinib 
per the dosing approaches outlined above. 
After 10 weeks on therapy, there was a 2-
week washout period, and patients were then 
switched to the other agent for 10 weeks of 
further therapy. The primary endpoint was 
patient preference between agents. Seventy 
percent preferred pazopanib, 22% sunitinib, 
and 8% expressed no preference. The main 
drivers were fatigue and overall quality of life 
(QOL). The conclusion of the authors was 
that pazopanib was preferred by patients. 
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Figure 1. Treatment decision tree for first- and second-line therapy in metastatic renal cell carcinoma 
based on available and evolving evidence. Bev: bevacizumab; HFS: hand foot syndrome; IFNα: 
interferon alfa; PFS: progression free survival. 
As a result of these two trials, both funded 
by GlaxoSmithKline, there appears to be a  
preference for pazopanib in the community 
and in many academic centers. However, 
when interpreting the results of COMPARZ 
and PISCES, one must take into account a 
few important considerations. First, although 
not in the product label, many clinicians 
have subsequently switched from a 4-week 
on and a 2-week off schedule for sunitinib to 
Table 2. Results of landmark(s) trials of FDA-approved agents in the treatment of 
metastatic renal cell carcinoma in first- and second-line 
Agents Comparator Study year for 
OS results 
Median PFS, 
mo 
Median OS, mo 
First-line 
Pazopanib Placebo 2013 (45) 11.1 vs 2.8* 22.9 vs 20.5 
Bev + IFN-α IFN-α 2010 (21, 24) 10.2 vs 5.4*  
8.5 vs 5.2* 
23.3 vs 21.3, 
18.3 vs 17.4 
Sorafenib IFN-α 2009 (26) 5.7 vs 5.6 Not reported 
Sunitinib IFN-α 2009 (18) 11 vs 5* 26.4 vs 21.8 
Temsirolimus** IFN-α 2007 (17) 5.5 vs 3.1 10.9 vs 7.3* 
Second-line 
Nivolumab Everolimus 2015 (2) 4.6 vs 4.4 25.0 vs 19.6* 
Axitinib Sorafenib 2011 (32) 6.7 vs 4.7*  
Everolimus Placebo 2010 (35) 4.9 vs 1.9* 14.8 vs 14.4 
*Statistically significant. 
**For poor-risk patients by MSKCC criteria. 
Bev: bevacizumab; HD: high dose; IFN-α: interferon alfa; mo: month; OS: overall survival; 
PFS: progression-free survival. 
Pazopanib 
Transaminitis and 
hair color changes 
more common 
Poor Risk 
Consider 
Temsirolimus 
Intermediate 
risk  
Sunitinib  
Fatigue, HFS, taste 
changes, mucositis, 
& hematologic  
toxicities more 
common 
 
Alternatives  
 Bev/IFN 
burdensome 
 Sorafenib lacks 
compelling 
evidence 
Axitinib 
Superior PFS vs 
sorafenib  
hypertension, diarrhea, 
fatigue more common 
Everolimus 
Superior PFS vs placebo  
Mucositis, 
hyperglycemia, altered 
lipid profiles more 
common 
 
Good Risk 
Consider  
IL-2 
First-line 
New agents 
 Nivolumab 
 Cabozatinib 
 Others? 
Second-line 
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a 2-week on and a 1-week off schedule. Early 
trials have shown improved tolerability with 
no impact on outcomes (16). It is unknown 
what impact this change in schedule would 
have on HRQoL patients shown in the 
COMPARZ and PISCES trials. 
Another key is that the timing of 
assessments in the trials may have biased in 
favor of pazopanib by assessing tolerability at 
the end of the 4 weeks on therapy with 
sunitinib. This represents the time of 
maximum toxicity. If taken after the two off 
weeks, the HRQoL may have been better in 
the sunitinib arm. Despite these concerns, 
the data from COMPARZ and PISCES 
represent the best available information with 
which to choose between the agents. 
Poor-risk patients: role of temsirolimus 
In the same way that IL-2 has a specific 
indication in the particularly fit patient, 
temsirolimus has a niche in poor-risk 
patients. In the phase III trial of the agent, 
626 treatment naïve patients were given 
weekly temsirolimus, temsirolimus plus 
interferon-alfa, or interferon-alfa alone (17). 
Monotherapy with temsirolimus was 
superior to interferon-alfa in terms of OS 
(10.9 vs 7.3 months, HR, 0.83 [95% CI, 
0.58–0.92]). The combination arm was 
similar to interferon-alfa monotherapy at 
8.4 months. A similar superiority for 
temsirolimus monotherapy was seen in PFS. 
No other agents have data specifically 
supporting their use in the poor-risk space. 
For example, the pivotal trials for sunitinib 
and pazopanib included very few poor-risk 
patients at only 6% and 3%, respectively 
(18, 19). The subset was, therefore, not 
large enough to provide compelling data as 
to their role. There is an ongoing phase II 
trial comparing temsirolimus with 
pazopanib, which will further define the 
role of temsirolimus, as will ongoing real-
world analyses (20). 
Other considerations 
 Other approved regimens: Although 
bevacizumab plus interferon-alfa has a 
category 1 indication in the NCCN 
guidelines based on the AVOREN and 
CALGB 90206 (Cancer and Leukemia 
Group B 90206) results, no trial has 
demonstrated an OS benefit for the 
addition of bevacizumab. We do not 
favor this regimen because of the 
toxicities of interferon, the need for 
frequent subcutaneous and intravenous 
administration of the agents, and the 
availability of the other orally 
administered agents discussed above 
(21–24). Sorafenib does not have a 
category 1 indication because TARGET 
(Treatment Approaches in Renal Cancer 
Global Evaluation Trial) did not show an 
OS benefit, and the previous phase II did 
not show a PFS advantage when 
compared to interferon-alfa (25–27). 
 Combinations of agents: Numerous 
trials have looked at combinations of 
agents, hoping to demonstrate 
synergistic effects and tolerable side 
effects, but they have not been shown 
to be beneficial. An example is the 
BEST (BEvacizumab, Sorafenib, and 
Temsirolimus) trial that compared 
bevacizumab, bevacizumab plus 
temsirolimus, bevacizumab plus 
sorafenib, and sorafenib plus 
temsirolimus (28). No combination arm 
showed superiority with a PFS of 8.7 
months for monotherapy vs 7.3, 11.3, 
and 7.7 months for the other arms, 
respectively. An exception to this lack of 
benefit to combination therapies can be 
seen with the recent evidence showing 
benefit for the combination of lenvatinib 
and everolimus in the second-line as 
presented subsequently. 
Real-world practice patterns 
The use of data generated in clinical 
practice to inform treatment considerations 
has not been fully realized. A recent article 
compared patients included in the pivotal 
clinical trials with those treated with 
sunitinib, sorafenib, pazopanib, and 
temsirolimus in the community. The “real-
world” cohort were part of a joint academic-
community registry (29). Overall, 39% of 
the registry patients would not have met the 
inclusion and/or exclusion criteria for the 
relevant pivotal trial used to approve 
the drug that they received. As an example, 
among the 438 community patients, those 
who received tyrosine kinase inhibitors 
(TKIs) were more likely to have poor-risk 
disease (7.4% vs 2.9%, P<0.001) and less 
likely to have favorable disease (30.1% vs 
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43.8%, P<0.001) when compared with those 
in the trials. Those treated with temsirolimus 
were less likely to have poor-risk disease 
(10.2% vs 69.4%) when compared with those 
in the trial, despite poor risk being the 
indication for the use of the agent. 
These findings beg the question of whether 
those patients treated in the community have 
similar outcomes and toxicity profiles with 
those who participate in the clinical trials 
used to approve a given agent. An abstract 
presented at the ASCO Genitourinary 
Meeting in January 2016 described outcomes 
of USON patients treated with pazopanib or 
sunitinib in the first-line (30). Median PFS 
was 9.3 months with pazopanib and 8.3 
months with sunitinib when compared with 
11 and 11.1 months in the pivotal trials, as 
shown in Table 2. Median OS was also 
similar between the two agents at 22.3 and 
26.3 months in the USON retrospective 
cohorts, respectively, when compared with 
22.9 and 26.4 months in the pivotal trials. 
These results are reassuring that the 
outcomes are not dramatically different in 
our experience overall, or by agent. In the 
USON retrospective series, adverse events 
(any grade), including anorexia, skin toxicity, 
and stomatitis, were significantly less 
common among pazopanib-treated patients 
(P<0.05), whereas diarrhea, hypertension, 
nausea, and vomiting were significantly less 
common with sunitinib (P<0.05). Patients 
treated with sunitinib also appeared to have 
higher incidence of headache and pain in an 
extremity although the difference was not 
statistically significant. 
A similar analysis of the community-
academic registry as to the rate of adverse 
events is instructive in showing the 
tolerability of these agents in practice (7). 
Of the 466 patients captured in the real-
world registry, 57% experienced fatigue 
that was severe enough to lead to 
documentation in the chart, 40% vomiting, 
34% diarrhea, 33% asthenia, and 21% 
mucosal inflammation. This demonstrates 
the frequency of difficulties with tolerance 
in this patient population. When looking at 
sunitinib, only 46% of patients remained 
on full-dose therapy (50 mg) by the end of 
therapy. Sixteen percent were on a dose of 
25 mg or below, calling into question the 
effectiveness of the therapy being provided 
in these instances. 
In order to optimally manage these patients, 
we must ensure that effectiveness and 
tolerability in practice are documented, and 
disseminated to the treatment community. A 
recent survey of medical oncology experts 
representing 11 cancer centers of excellence 
from around the world assessed variations in 
treatment approaches (31). The authors found 
great heterogeneity in decision criteria and 
were struck by how “differently the available 
data are interpreted and implemented by 
experts.” This shows the difficulty in applying 
the available results from clinical trials to 
patients in the real world. 
US Oncology Network approach 
We recommend either pazopanib or sunitinib 
as first-line options in the treatment of mRCC. 
If sunitinib is used, we often use a dose and 
schedule of 50 mg daily for 2 weeks on and 1 
week off based on the data suggesting better 
tolerability although we acknowledge that the 
quality of the data is not of the highest level. 
Although temsirolimus is certainly reasonable 
in poor-risk patients, the authors are nearly 
evenly split on its use in practice as the 
preferred agent. Four use it regularly, one 
uses it occasionally, and the remaining three 
do not use it, instead giving pazopanib or 
sunitinib. IL-2 is rarely used as well. Because 
of the toxicity and need for hospitalization, we 
recommend administration only in high-
volume centers with considerable experience 
and in otherwise healthy, younger patients. 
Among the authors, all consider 
administering it, yet some have never given it 
and others do so quite rarely. With the 
introduction of immunotherapies, the 
pendulum is likely to swing yet further away. 
The hope is that, as real-world data are 
increasingly refined, they could be used to 
simplify the treatment algorithm yet further 
based on the balance of relative value and 
the validation of findings such as the rate of 
CR with IL-2 and preferential utility of 
temsirolimus in the identified niche. To take 
this one step further, the hope is to 
personalize treatments for a given patient 
based on their unique characteristics such 
as age, comorbidities, and goals of care. 
Standard of care in the second-line 
Second-line therapy is changing. Per the 
NCCN guidelines, if patients receive either 
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IL-2 or temsirolimus in the first-line, they 
should receive either pazopanib or sunitinib 
in the second-line. However, for those who 
receive either pazopanib or sunitinib in the 
first-line, the choice in the second-line is less 
straightforward. There is evidence to support 
both a mammalian target of rapamycin 
(mTOR) inhibitor and a TKI. The preferred 
agent has not been clearly demonstrated. 
Axitinib vs everolimus 
Axitinib was approved based on the AXIS 
(Axitinib versus Sorafenib in Advanced 
Rena Cell Carcinoma) trial in which 723 
patients were randomized to axitinib or 
sorafenib (32). All had received one prior 
therapy. The median PFS for axitinib was 
8.3 vs 5.7 months with sorafenib (HR, 
0.665, 95% CI, 0.544–0.812). There was no 
difference in OS. The most common side 
effects with axitinib were diarrhea, 
hypertension, and fatigue. These findings 
established axitinib as the preferred choice 
over sorafenib in the second-line setting. 
Everolimus was approved based on the 
RECORD-1 (Renal Cell Cancer Treatment 
with Oral RAD001 given daily) results in 
which it was compared to placebo (33–35). 
In the trial, 410 patients were assigned 2:1 
to everolimus or placebo. All had received at 
least one, if not two, prior treatments with 
sunitinib and/or sorafenib. The median PFS 
for everolimus was 4.0 vs 1.9 months with 
placebo. No OS impact was seen in the trial 
although the crossover rate was over 90%. It 
was also clear that there was benefit for 
everolimus as a third-line agent. The most 
common adverse events with everolimus 
included stomatitis, rash, and fatigue. 
Pneumonitis occurred in 8% of patients. 
Because there was not a head-to-head 
comparison, it is difficult to decide which 
agent is preferred to date in the second-line. Is 
a TKI-mTOR strategy preferable to TKI-TKI? 
The INTORSECT (Investigating Torisel as 
Second-Line Therapy) trial is somewhat 
instructive. In this trial of patients previously 
treated with sunitinib, the PFS results were 
similar whether a patient was treated with 
mTOR or TKI in the second-line (4.3 vs 3.9 
months, HR, 0.87 [95% CI, 0.71–1.07]); 
however, OS was inferior in the TKI-mTOR 
group at 12.3 vs 16.6 months (HR, 1.31 [95% 
CI, 1.05–163]). The greatest benefit of the TKI-
TKI approach was seen in patients who had 
over 6 months of response to sunitinib in the 
first-line. A factor in favor of axitinib over 
everolimus is its ability to produce responses: 
axitinib produces a response rate of about 
20% in the second-line setting, whereas the 
response rate of everolimus is <5%. 
Despite the three large trials discussed 
(RECORD-1, AXIS, and INTORSECT), there is 
not a clear treatment of choice in the second-
line to date between axitinib and everolimus. 
INTORSECT looked at temsirolimus, which is 
not the agent used in the second-line, 
RECORD-1 compared the agent with placebo, 
and no trials showed an OS benefit. Although 
the details are indeed thought provoking, 
they require assessment in the real world, if 
not a prospective trial, in order to answer the 
question of what agent to use. An example of 
such an analysis can be seen in an article 
that is presently undergoing peer review, in 
which the real-world experiences with 
axitinib and everolimus were compared (36). 
The results showed that PFS did not differ 
significantly between everolimus and axitinib 
(HR, 1.16 [95% CI, 0.73–1.82]). However, 
axitinib was associated with 17% higher drug 
costs per month of PFS at $12,467 vs 
$10,637 (P<0.001). This is an example of how 
real-world data can be used to advance 
treatment paradigms. 
Evolving second-line literature: roles of 
nivolumab, cabozantinib, and lenvatinib 
Nivolumab is a monoclonal antibody directed 
at programmed death (PD)-1. Inhibition of 
PD-1 by nivolumab drives T-cell immunity 
and has been successful in treating non-
small-cell lung cancer and melanoma among 
other cancer types. In a phase III trial, 821 
patients with mRCC with a clear cell 
component were randomly assigned to 
receive either nivolumab or everolimus and 
treated until progression or unacceptable 
toxicity (2). Nivolumab was administered at a 
dose of 3 mg/kg intravenously every 2 
weeks, and everolimus was administered at a 
dose of 10 mg orally daily. PFS was not 
significantly different at 4.6 months with 
nivolumab vs 4.4 months with everolimus; 
however, OS was 25.0 and 19.6 months (HR, 
0.73 [95% CI, 0.57–0.93]), respectively. 
Overall response rate (ORR) was 25% with 
nivolumab vs 5% with everolimus, with 
similar CR rates of 1% and <1%. Responses 
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were consistent across subgroups of MSKCC 
risk and PD-L1 status. The rate of grade 3 or 
4 toxicity was preferable for nivolumab at 
19% vs 37% with everolimus. This trial 
demonstrated the efficacy of nivolumab in 
treating mRCC and resulted in the Food and 
Drug Administration (FDA) approval on 
November 23, 2015. We predict that 
nivolumab will be widely used in the 
treatment of patients with mRCC after failure 
of a TKI. The role of immune checkpoint 
inhibitors in the first-line setting is being 
actively investigated in clinical trials. 
Although checkpoint inhibitors garner much 
of the attention, other promising results from 
agents are being studied. Cabozantinib 
(Cometriq, Exelixis) is an oral, small-molecule 
TKI, a different target profile (37). In the 
METEOR trial (A Trial of Cabozatinib (XL184) 
vs Evereolimus in Subjects with Metastatic 
Renal Cell Carcinoma), 658 patients with 
metastatic kidney cancer and a clear cell 
component were randomly assigned to either 
cabozantinib at 60 mg orally daily or 
everolimus at 10 mg orally daily (3). Patients 
had to have received at least one prior TKI. 
The median PFS was 7.4 with cabozantinib vs 
3.8 months with everolimus (HR, 0.58 [95% 
CI, 0.45–0.75]). The ORR was 21% vs 5% 
(P<0.001). Although there was a trend in 
favor of improved OS with cabozantinib (HR, 
0.67 [95% CI, 0.51–0.89]), it did not meet the 
predefined boundary for the interim analysis. 
The data will continue to mature. The main 
concern is that 60% of patients in the 
cabozatinib arm required dose reductions vs 
25% of patients in the everolimus arm. The 
discontinuation rates were similar at 9% and 
10%, respectively. The conclusion of this 
study is that, as a therapy for RCC refractory 
to prior TKI therapy, cabozantinib improves 
PFS when compared with everolimus. The 
response rate was similar to axitinib. 
Whether cabozantinib offers advantages over 
axitinib, the TKI already FDA approved in the 
same setting, is unclear. Cabozantinib has 
not been FDA approved for RCC (although it 
is approved for medullary thyroid cancer) at 
the time of this writing. 
Finally, a phase II trial was published in The 
Lancet on October 15, 2015, that assessed 
lenvatinib, everolimus, and lenvatinib/ 
everolimus in the second-line among 153 
mRCC patients (38). Mouse models have 
shown that the fibroblast growth factor (FGF) 
may be a mechanism of resistance to TKIs. 
Lenvatinib has a unique mechanism of action 
in that it is a potent inhibitor of both VEGF 
and FGF receptors, potentially providing 
benefit despite progression on a prior TKI. 
Lenvatinib use in combination with an mTOR 
inhibitor showed yet greater activity in these 
models. The phase III study showed that the 
combination significantly prolonged PFS 
when compared with everolimus alone at 
14.6 vs 5.5 months (HR, 0.40 [95% CI, 0.24–
0.68]) but not with lenvatinib alone at 14.6 vs 
7.4 months (HR, 0.66 [95% CI, 0.30–1.1]). 
Grade 3 or 4 events occurred in 71% of those 
receiving combination therapy, 79% of 
lenvatinib-treated patients, and 50% of 
everolimus-treated patients. No survival data 
are yet available. 
Real-world practice patterns and the USON 
pathways 
Nivolumab is likely to become the new 
standard of care in the second-line based on 
the data showing a preferential toxicity profile, 
higher response rate, and 5.4-month 
improvement in OS. Axitinib is still a 
reasonable option after failure of a prior TKI; 
however, we predict that the novel 
mechanism of action of nivolumab, the proven 
survival advantage (which axitinib does not 
have), and the general excitement within the 
oncology community about checkpoint 
inhibitors will lead to the use of nivolumab. 
Axitinib may instead be used as third-line. If 
cabozantinib becomes approved by the FDA, 
it could also be used as a third-line treatment. 
Decisions will likely be based on cost, toxicity 
profile, patient preference, and results of 
published follow-up. An ongoing trial 
comparing cabozantinib with sunitinib in the 
first-line has completed accrual (39). 
Evolving literature and next steps 
We predict that there will be extensive study 
of combinations of agents such as 
nivolumab with sunitinib, pazopanib, or 
ipilimumab (40). Although combinations 
have proven difficult in RCC, the toxicity 
profile and response of nivolumab may 
make its use in combination a viable option. 
Over the next few years, the role of 
checkpoint inhibitors will evolve further as 
other agents are approved, as has occurred 
with TKI and mTOR inhibitors, and as 
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first-line trials read out. Combinations of 
checkpoint inhibitors and anti-angiogenic 
agents will continue to be studied although 
early trials have shown significant toxicity. 
A phase 1 trial looking at nivolumab with 
either sunitinib or pazopanib showed that 
73% and 60% of patients experienced 
grade 3 or 4 toxicities, respectively (41). 
Dual checkpoint inhibition—such as 
combining a PD-1 antibody like nivolumab 
with an alternative immunotherapy—is 
being studied. Nivolumab with ipilimumab 
(Yervoy, Bristol Meyers Squibb) was first 
approved on October 1, 2015, for the 
treatment of metastatic melanoma. A 
similar trial in mRCC is ongoing 
(CheckMate 214). In metastatic melanoma, 
the combination improved PFS from 4.7 
with ipilimumab alone to 8.9 months with 
the combination (42). 
There are other classes of agents in the 
pipeline as well. An example is the promise 
of autologous dendritic cell immunotherapy. 
The ADAPT (Autologous Dendritic Cell 
Immunotherapy Plus Standard Treatment of 
Advanced Renal Cell Carcinoma) trial of 
autologous dendritic cell immunotherapy 
has completed enrollment of 450 patients as 
of July 2015 (43). The agent, AGS-003, is 
being given in conjunction with sunitinib in 
newly diagnosed patients to assess the 
effect of a combined approach of TKI and 
immunotherapy. Data from the phase III 
IMPRINT (IMA901 in Patients Receiving 
Sunitinib for Advanced/Metastatic Renal 
Cell Carcinoma) trial looking at IMA901, a 
vaccine in combination with sunitinib, were 
presented at the European Cancer Congress 
in late 2015 and did not meet the primary 
endpoint of an extension in OS (44). 
Beyond the introduction of new agents, the 
utility of data and informatics to drive care 
is promising. Groups such as the USON 
are establishing systems and approaches 
that will leverage data from electronic 
health records, genomic analyses, and 
other systems to assess risk, improve 
understanding of the optimal role for 
specific agents, and provide clinical 
decision support to enable personalized 
recommendations. Real-world data could 
be used to update the analyses and help to 
further define the roles of available agents. 
It is likely that the output would be more 
nuanced and complex than prior 
approaches; however, it could be supported 
with available systems. 
Conclusions 
Although the mRCC treatment landscape 
can seem quite complex and overwhelming, 
the approach to treatment is relatively 
straightforward. Pazopanib and sunitinib 
represent the standard-of-care options we 
prefer for initial therapy in most patients 
with metastatic disease, with temsirolimus 
and IL-2 playing a role in limited 
situations. Nivolumab was recently 
approved by the FDA and will likely become 
the preferred second-line therapy. Axitinib 
is also reasonable to use in the second-line 
setting. Cabozantinib appears promising, 
but is not yet FDA approved. We suspect 
that axitinib and cabozantinib will begin to 
be used as third-line agents, with 
everolimus reserved for fourth-line. 
Sorafenib is also available, but its role at 
this point has become unclear. Finally, we 
encourage our patients to consider clinical 
trials, so that they may have access to the 
latest discoveries and contribute to finding 
a cure for kidney cancer. 
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